# US 7,410,767 B1 · HLA-E binding > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,410,767 B1 - Document ID: US7410767B1 - Status: Granted - Kind: B1 - Application number: 09/555,555 - Filed: 1998-12-04 - Granted: 2008-08-12 - Earliest claimed: 1997-12-04 - Assignees: Isis Innovation Limited - Inventors: Veronique M. Braud; David S. J. Allan; Graham S. Ogg; Christopher A. O'Callaghan; Andrew J. McMichael - Web page: https://patentgrep.com/patent/US7410767B1 ## CPC - C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere} - A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives - A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 31/12: Antivirals - A61P 31/18: for HIV - A61P 31/22: for herpes viruses - A61P 35/00: Antineoplastic agents - A61P 35/02: specific for leukemia - A61P 37/00: Drugs for immunological or allergic disorders - A61P 37/02: Immunomodulators - A61P 37/04: Immunostimulants - A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection - C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72} - G01N 33/56977: {HLA or MHC typing} - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - G01N 2333/70539: MHC-molecules, e.g. HLA-molecules - G01N 2333/7056: Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The invention relates to a method of testing a compound for biological activity, which method comprises providing cells expressing one of the CD94/NKG2 family of receptors, contacting the cells with recombinant HLA-E under binding conditions in the presence of the test compound, and determining whether the presence of the compound affects the binding of HLA-E to the cells. The HLA-E property of binding to CD94/NKG2 receptors on NK cells and a subset of CD8+ T cells is useful for targeting CD94/NKG2+ cells for a variety of purposes such as identification, isolation, killing or inactivation. ## Claims ### Claim 1 A method of testing a compound for biological activity, which method comprises: (i) providing cells expressing a CD94/NKG2 receptor, wherein the NKG2 member is selected from the group consisting of NKG2A, NKG2B, NKG2C, NKG2E, and NKG2F at the cell surface; (ii) contacting the cells with HLA-E in the presence of the test compound; and (iii) determining whether the presence of the compound affects the binding of HLA-E to the cells. ### Claim 2 (depends on 1) The method according to claim 1, wherein the CD94/NKG2 receptor is an inhibitory NK cell receptor. ### Claim 3 (depends on 1) The method according to claim 1, wherein the CD94/NKG2 receptor is a stimulatory NK cell receptor. ### Claim 4 (depends on 1) The method according to claim 1, wherein the NKG2 member is NKG2A. ### Claim 5 (depends on 1) The method according to claim 1, wherein the NKG2 member is NKG2C. ### Claim 6 (depends on 1) The method according to claim 1, wherein the NKG2 member is NKG2B. ### Claim 7 (depends on 1) The method according to claim 1, wherein the NKG2 member is NKG2E. ### Claim 8 (depends on 1) The method according to claim 1, wherein the NKG2 member is NKG2F. ### Claim 9 (depends on 1) The method of claim 1, wherein the test compound is an antibody. ### Claim 10 A method of identifying a compound affecting the binding of HLA-E to CD94/NKG2 receptors, which method comprises: (i) providing cells expressing a CD94/NKG2 receptor at the cell surface, wherein the NKG2 member is selected from a group consisting of NKG2A, NKG2B, NKG2C, NKG2E, and NKG2F; (ii) contacting the cells with HLA-E in the presence of a test compound; and (iii) determining whether the presence of the compound affects the binding of HLA-E to the cells. ### Claim 11 (depends on 10) The method of claim 10, further comprising using the identified compounds in therapeutic applications, wherein the identified compounds are antibodies. ### Claim 12 (depends on 10) The method of claim 10, wherein the CD94/NKG2 receptor is an inhibitory NK cell receptor. ### Claim 13 (depends on 10) The method of claim 10, wherein the CD94/NKG2 receptor is a stimulatory NK cell receptor. ### Claim 14 (depends on 10) The method of claim 10, wherein the NKG2 member is NKG2A. ### Claim 15 (depends on 10) The method of claim 10, wherein the NKG2 member is NKG2C. ### Claim 16 (depends on 10) The method of claim 10, wherein the test compound is an antibody. ### Claim 17 A method for screening and producing an identified compound which affects the binding of HLA-E to CD94/NKG2 receptors, which method comprises: (i) selecting a test compound for screening; (ii) providing cells expressing a CD94/NKG2 receptor at the cell surface, wherein the NKG2 member is selected from a group consisting of NKG2A, NKG2B, NKG2C, NKG2E, and NKG2F; (iii) contacting the cells with HLA-E in the presence of the test compound; (iv) determining whether the presence of the test compound affects the binding of HLA-E to the cells thereby providing an identified compound; and (v) producing the identified compound which affects the binding of HLA-E to the cells. ### Claim 18 (depends on 17) The method of claim 17, wherein the CD94/NKG2 receptor is an inhibitory NK cell receptor. ### Claim 19 (depends on 17) The method of claim 17, wherein the CD94/NKG2 receptor is a stimulatory NK cell receptor. ### Claim 20 (depends on 17) The method of claim 17, wherein the NKG2 member is NKG2A. ### Claim 21 (depends on 17) The method of claim 17, wherein the NKG2 member is NKG2C. ### Claim 22 (depends on 17) The method of claim 17, wherein the test compound is an antibody.